We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$10B
AUM Growth
+$66.4M
Cap. Flow
+$419M
Cap. Flow %
4.17%
Top 10 Hldgs %
49.99%
Holding
98
New
7
Increased
30
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$282M
2
CELC icon
Celcuity
CELC
+$271M
3
ERAS icon
Erasca
ERAS
+$189M
4
TNGX icon
Tango Therapeutics
TNGX
+$164M
5
IRTC icon
iRhythm Holdings
IRTC
+$70.2M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$269M
2
AXSM icon
Axsome Therapeutics
AXSM
+$162M
3
PODD icon
Insulet
PODD
+$92.3M
4
MASI
Masimo
MASI
+$88.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$85.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
26
Immatics
IMTX
$1.29B
$127M 1.26%
12,869,340
+1,435,986
+13% +$14.1M
ZLAB icon
27
Zai Lab
ZLAB
$2.91B
$124M 1.23%
6,574,032
-385,000
-6% -$7.14M
BLTE
28
Belite Bio
BLTE
$6.53B
$114M 1.13%
715,332
– –
ISRG icon
29
Intuitive Surgical
ISRG
$139B
$101M 1.01%
220,000
+118,772
+117% +$60.1M
ORKA
30
Oruka Therapeutics
ORKA
$7.35B
$101M 1%
2,058,148
– –
GHRS icon
31
GH Research
GHRS
$2.02B
$83.4M 0.83%
5,933,815
– –
XNCR icon
32
Xencor
XNCR
$1.74B
$81.7M 0.81%
6,777,461
– –
URGN icon
33
UroGen Pharma
URGN
$2.35B
$81.7M 0.81%
4,543,895
– –
CNTA
34
DELISTED
Centessa Pharmaceuticals
CNTA
$81.6M 0.81%
2,054,175
+263,338
+15% +$6.74M
IMVT icon
35
Immunovant
IMVT
$8.64B
$78.9M 0.79%
3,177,849
-1
-0% -$26
RARE icon
36
Ultragenyx Pharmaceutical
RARE
$2.61B
$76.4M 0.76%
3,648,795
+648,656
+22% +$14.6M
HNGE
37
Hinge Health
HNGE
$7.14B
$74.4M 0.74%
1,930,000
+1,576,500
+446% +$65.5M
CSTL icon
38
Castle Biosciences
CSTL
$905M
$67.7M 0.67%
2,758,335
+643,098
+30% +$21.1M
RCKT icon
39
Rocket Pharmaceuticals
RCKT
$381M
$63.3M 0.63%
17,687,772
– –
TSHA icon
40
Taysha Gene Therapies
TSHA
$1.9B
$61.2M 0.61%
13,680,248
-2,718,049
-17% -$12.6M
ALKS icon
41
Alkermes
ALKS
$8.23B
$59.1M 0.59%
1,672,356
– –
CMPS
42
Compass Pathways
CMPS
$1.86B
$58.8M 0.59%
10,632,390
+1,875,000
+21% +$12.6M
KOD icon
43
Kodiak Sciences
KOD
$2.59B
$56.7M 0.56%
1,487,934
+1
+0% +$26
REPL icon
44
Replimune Group
REPL
$1.4B
$56.3M 0.56%
7,356,916
+216,564
+3% +$1.66M
CRNX icon
45
Crinetics Pharmaceuticals
CRNX
$8.99B
$52.7M 0.52%
1,451,326
+100,000
+7% +$4.47M
QURE icon
46
uniQure
QURE
$3.37B
$42.3M 0.42%
2,586,356
-1,125,106
-30% -$22.8M
WAY
47
Waystar Holding Corp
WAY
$4.75B
$39.3M 0.39%
+1,630,000
New +$43.3M
ARWR icon
48
Arrowhead Research
ARWR
$12.2B
$36.7M 0.37%
585,682
+966
+0.2% +$61.1K
OBIO icon
49
Orchestra BioMed
OBIO
$265M
$35.3M 0.35%
8,306,063
– –
VSTM icon
50
Verastem
VSTM
$596M
$34.9M 0.35%
6,576,306
– –
1
2
3 4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q1 2026 Portfolio in Review

As of Q1 2026, RTW Investments held 98 positions worth $10B, up 0.67% from $9.98B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments deployed $419M of net new capital in Q1 2026, opening 7 new positions and adding to 30 existing holdings. Its largest new stake was Waystar Holding Corp: 1,630,000 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $85.8M trimmed.

  • RTW Investments's largest Q1 2026 buy was Waystar Holding Corp: 1,630,000 shares worth $39.3M.
  • RTW Investments added most to CG Oncology in Q1 2026, an estimated $282M increase.
  • RTW Investments's biggest Q1 2026 reduction was Apellis Pharmaceuticals, cutting an estimated $85.8M.
  • RTW Investments fully exited Penumbra in Q1 2026, selling an estimated $269M.
  • RTW Investments's ten largest holdings make up 50% of its $10B portfolio in Q1 2026.
  • RTW Investments opened 7 new positions and closed 10 in Q1 2026.
  • RTW Investments's portfolio value rose 0.67% quarter-over-quarter to $10B.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.